One-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis
GOLDENEYE
1 other identifier
observational
376
1 country
1
Brief Summary
Background: The GOLDENEYE study is an international, multicenter, prospective observational investigation designed to compare the outcomes of various management strategies for acute cholecystitis in patients aged 70 years and older. This research is driven by the increasing prevalence of gallstones and biliary tract diseases in the elderly, alongside a recognition that the burden of comorbidity in this population may necessitate tailored treatment approaches to optimize outcomes. Patients and Methods: The primary aims of the study are to evaluate the efficacy of different treatments -supportive care, percutaneous gallbladder drainage, early or delayed cholecystectomy, and EUS-guided gallbladder drainage- on patient-centric outcomes, including one-year additional treatment modalities, hospital readmissions, outpatient encounters, quality of life, and survival rates. The study adopts a robust design incorporating propensity score matching analysis to account for the non-randomized allocation of treatment modalities, thereby minimizing selection bias and enhancing the comparability of treatment groups. Inclusion criteria are centered on patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines, while key exclusion criteria include prior episodes of cholecystitis or pancreatitis, terminal illness, and concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy. Data collection will leverage the REDCap platform for systematic and secure data management, facilitating real-time data entry and monitoring across participating centers. Discussion: This comprehensive approach ensures the integrity and reliability of data collected on demographics, gender, clinical outcomes, and quality of life measures. Through its innovative design and methodology, the GOLDENEYE study aims to generate evidence-based insights that will significantly influence the management of acute cholecystitis in the elderly, ultimately improving patient outcomes and healthcare practices in this growing demographic population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2025
CompletedStudy Start
First participant enrolled
May 15, 2025
CompletedFirst Posted
Study publicly available on registry
June 5, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 15, 2027
June 8, 2025
May 1, 2025
2 years
May 14, 2025
June 6, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
1 year additional procedures, hospital readmissions or outpatient visits
Percentage of patients requiring any additional procedure, hospital readmission or outpatient visit during the first year.
1 year
Secondary Outcomes (2)
1-year health-related quality of life
1 year
1-year overall survival
1 year
Study Arms (4)
Supportive care
Patients that received antibiotics only
Cholecystectomy
Patients that undergo early or delayed cholecystectomy
percutaneous gallbladder drainage
Patients that undergo percutaneous gallbladder drainage
EUS-guided gallbladder drainage
Patients that undergo EUS-guided gallbladder drainage
Eligibility Criteria
Patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines
You may qualify if:
- patients ≥70 years
- diagnosed with acute cholecystitis, as per the Tokyo guidelines
You may not qualify if:
- prior episodes of cholecystitis or pancreatitis
- terminal illness
- concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)
Alicante, Alicante, 03010, Spain
Related Publications (1)
Lluis N, Perez-Brotons S, de Castro I, Martinez B, Aparicio JR, Zapater P, Lluis F, de-Madaria E. One-year outcomes by index treatment in older patients with acute cholecystitis. Protocol of the international, prospective, observational GOLDENEYE study. Cir Esp (Engl Ed). 2025 Dec 23:800282. doi: 10.1016/j.cireng.2025.800282. Online ahead of print.
PMID: 41448354DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
May 14, 2025
First Posted
June 5, 2025
Study Start
May 15, 2025
Primary Completion (Estimated)
May 15, 2027
Study Completion (Estimated)
May 15, 2027
Last Updated
June 8, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share
The Steering Committee and statistical advisors will have access to the final dataset. Members of the GOLDENEYE study that recruited patients may claim access to the final dataset to perform ancillary studies; the Steering Committee will study these proposals. Any data required to support the protocol can be supplied on request.